What is Apimeds Pharmaceuticals US, Inc.'s Market Cap?

Apimeds Pharmaceuticals US, Inc.'s Market Cap is $3.5M, based on as-reported figures from SEC (XBRL) filings.

What is Apimeds Pharmaceuticals US, Inc.'s Enterprise Value?

Apimeds Pharmaceuticals US, Inc.'s Enterprise Value is $1.1M, based on as-reported figures from SEC (XBRL) filings.

What is Apimeds Pharmaceuticals US, Inc.'s EV / EBITDA?

Apimeds Pharmaceuticals US, Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.

What is Apimeds Pharmaceuticals US, Inc.'s Revenue (TTM)?

Apimeds Pharmaceuticals US, Inc.'s Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.

What is Apimeds Pharmaceuticals US, Inc.'s Net Income (TTM)?

Apimeds Pharmaceuticals US, Inc.'s Net Income (TTM) is -$40.7M, based on as-reported figures from SEC (XBRL) filings.

What is Apimeds Pharmaceuticals US, Inc.'s EBITDA?

Apimeds Pharmaceuticals US, Inc.'s EBITDA is -$23.7M, based on as-reported figures from SEC (XBRL) filings.

What is Apimeds Pharmaceuticals US, Inc.'s Diluted EPS (TTM)?

Apimeds Pharmaceuticals US, Inc.'s Diluted EPS (TTM) is -26.94, based on as-reported figures from SEC (XBRL) filings.

What is Apimeds Pharmaceuticals US, Inc.'s Net Debt?

Apimeds Pharmaceuticals US, Inc.'s Net Debt is -$2.5M, based on as-reported figures from SEC (XBRL) filings.

Apimeds Pharmaceuticals US, Inc. (APUS) Financial Statements

Apimeds Pharmaceuticals US, Inc.

SIC 2834 · PHARMACEUTICAL PREPARATIONS

FIGI BBG01Q0T3FL7

XASE · usd

2.30▼ 0.12 (-4.96%)

As of 2026-09-08

Valuation

Market Cap

Enterprise Value

Trailing P/E—

Price / Sales—

EV / Revenue—

EV / EBITDA

Financial Highlights

Revenue (TTM)

Net Income (TTM)

EBITDA

Diluted EPS (TTM)

EBITDA Margin—

Net Debt

Trading Information

Previous Close2.42

Day's Range2.25 – 2.41

52-Week Range0.61 – 8.28

Volume17.3K

Avg Volume129.5K

Share Statistics

Shares Outstanding

Employees2

ExchangeXASE

Listed2025-05-09

Share count as of August 12, 2026

ViewDetail

Period

Loading Income Statement…

Key questions about Apimeds Pharmaceuticals US, Inc. (APUS)

What is Apimeds Pharmaceuticals US, Inc.'s Market Cap?: Apimeds Pharmaceuticals US, Inc.'s Market Cap is $3.5M, based on as-reported figures from SEC (XBRL) filings.
What is Apimeds Pharmaceuticals US, Inc.'s Enterprise Value?: Apimeds Pharmaceuticals US, Inc.'s Enterprise Value is $1.1M, based on as-reported figures from SEC (XBRL) filings.
What is Apimeds Pharmaceuticals US, Inc.'s EV / EBITDA?: Apimeds Pharmaceuticals US, Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Apimeds Pharmaceuticals US, Inc.'s Revenue (TTM)?: Apimeds Pharmaceuticals US, Inc.'s Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is Apimeds Pharmaceuticals US, Inc.'s Net Income (TTM)?: Apimeds Pharmaceuticals US, Inc.'s Net Income (TTM) is -$40.7M, based on as-reported figures from SEC (XBRL) filings.
What is Apimeds Pharmaceuticals US, Inc.'s EBITDA?: Apimeds Pharmaceuticals US, Inc.'s EBITDA is -$23.7M, based on as-reported figures from SEC (XBRL) filings.
What is Apimeds Pharmaceuticals US, Inc.'s Diluted EPS (TTM)?: Apimeds Pharmaceuticals US, Inc.'s Diluted EPS (TTM) is -26.94, based on as-reported figures from SEC (XBRL) filings.
What is Apimeds Pharmaceuticals US, Inc.'s Net Debt?: Apimeds Pharmaceuticals US, Inc.'s Net Debt is -$2.5M, based on as-reported figures from SEC (XBRL) filings.